Four key indicators of ATTR-Cardiac Amyloidosis (ATTR-CM) that showed a patient what was wrong with his heart

Ken’s search for answers brought him to nearly a dozen doctors. After months of tests, he was finally diagnosed with a rare ...
GitHub

jQuery contextMenu plugin & polyfill

$.contextMenu is a management facility for - you guessed it - context menus. It was designed for an application where there are hundreds of elements that may show a context menu - so intialization ...
IEEE

EPREAR:An Efficient Attribute-Based Proxy Re-Encryption Scheme With Fast Revocation for Data Sharing in AIoT

Abstract: The Artificial Intelligence of Things (AIoT) is driving human society from “information” to “intelligence”, and the information technology industry is undergoing tremendous changes. However, ...
BioSpace

Acoramidis Begins to Reduce Cumulative Cardiovascular Outcomes Within the First Month of Treatment in Patients with ATTR-CM

- Acoramidis significantly reduced the cumulative risk of CVM or recurrent CVH through Month 30 versus placebo with a 49% hazard reduction (p<0.0001) - The difference in cumulative events increased ...
Investing

Vutrisiran treatment reduces GI events in ATTR-CM patients by up to 49%

"As a multisystem disease, it is well-known that ATTR-CM impacts more than just the heart," said Marcus Urey, M.D., Associate Professor at University of California San Diego Health, in the press ...
rarediseaseadvisor

RN3271 Shows Promise for ATTR-CM

RN3271 showed deep and durable effects in reducing TTR protein with a favorable safety profile. MINNEAPOLIS— RN3271, a novel GalNAc-conjugated siRNA designed to silence transthyretin (TTR) expression ...
IEEE

TAFC: Time and Attribute Factors Combined Access Control for Time-Sensitive Data in Public Cloud

Abstract: The new paradigm of outsourcing data to the cloud is a double-edged sword. On the one hand, it frees data owners from the technical management, and is easier for data owners to share their ...
Yahoo Finance

Intellia Therapeutics Announces Positive Longer-Term Phase 1 Data for Nexiguran Ziclumeran (nex-z) in Patients with Hereditary Transthyretin (ATTR) Amyloidosis with Polyneuropathy

CAMBRIDGE, Mass., Sept. 25, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...
BioSpace

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR ...

Longer-term data to be presented at the 5th International ATTR Amyloidosis Meeting for Patients and Doctors on September 25 highlighting up to three years of patient follow-up and additional insight ...
GitHub

svg-pan-zoom library

If you found a bug or have a suggestion first check if there is a similar open or closed issue. If there are none then create a new one. If you solved a bug or implemented a feature that may be useful ...
Yahoo Finance

Intellia Therapeutics to Present Longer-Term Data from the Ongoing Phase 1 Clinical Trial of Nexiguran Ziclumeran (nex-z) for the Treatment of Hereditary Transthyretin (ATTR ...

CAMBRIDGE, Mass., Sept. 22, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, Inc. (NASDAQ:NTLA), a leading clinical-stage gene editing company focused on revolutionizing medicine with CRISPR-based ...